 Kintara Therapeutics Inc NASDAQ: KTRA has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center. The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase gene. 